MICROBIX BIOSYSTEMS INC (MBX.CA) Stock Fundamental Analysis
TSX:MBX - Toronto Stock Exchange - CA59501P1045 - Common Stock - Currency: CAD
MBX gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 24 industry peers in the Biotechnology industry. MBX scores excellent points on both the profitability and health parts. This is a solid base for a good stock. MBX is growing strongly while it also seems undervalued. This is an interesting combination With these ratings, MBX could be worth investigating further for value and growth and quality investing!.
1. Profitability
1.1 Basic Checks
In the past year MBX was profitable.
MBX had a positive operating cash flow in the past year.
In multiple years MBX reported negative net income over the last 5 years.
MBX had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
MBX has a better Return On Assets (3.97%) than 91.67% of its industry peers.
With an excellent Return On Equity value of 5.04%, MBX belongs to the best of the industry, outperforming 95.83% of the companies in the same industry.
MBX has a better Return On Invested Capital (4.29%) than 91.67% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.97% | ||
| ROE | 5.04% | ||
| ROIC | 4.29% |
ROA(3y)4.84%
ROA(5y)-2.84%
ROE(3y)6.48%
ROE(5y)-11.45%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Profit Margin value of 6.89%, MBX belongs to the best of the industry, outperforming 91.67% of the companies in the same industry.
MBX's Profit Margin has improved in the last couple of years.
MBX's Operating Margin of 9.61% is amongst the best of the industry. MBX outperforms 91.67% of its industry peers.
In the last couple of years the Operating Margin of MBX has grown nicely.
MBX's Gross Margin of 57.74% is amongst the best of the industry. MBX outperforms 87.50% of its industry peers.
MBX's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 9.61% | ||
| PM (TTM) | 6.89% | ||
| GM | 57.74% |
OM growth 3Y-14.86%
OM growth 5Y15.81%
PM growth 3Y-7.25%
PM growth 5Y128.26%
GM growth 3Y0.68%
GM growth 5Y4.41%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), MBX is destroying value.
MBX has less shares outstanding than it did 1 year ago.
The number of shares outstanding for MBX has been increased compared to 5 years ago.
MBX has a better debt/assets ratio than last year.
2.2 Solvency
MBX has an Altman-Z score of 3.36. This indicates that MBX is financially healthy and has little risk of bankruptcy at the moment.
MBX has a Altman-Z score of 3.36. This is amongst the best in the industry. MBX outperforms 91.67% of its industry peers.
The Debt to FCF ratio of MBX is 2.38, which is a good value as it means it would take MBX, 2.38 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of MBX (2.38) is better than 91.67% of its industry peers.
MBX has a Debt/Equity ratio of 0.17. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of MBX (0.17) is better than 62.50% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.17 | ||
| Debt/FCF | 2.38 | ||
| Altman-Z | 3.36 |
ROIC/WACC0.59
WACC7.29%
2.3 Liquidity
MBX has a Current Ratio of 9.36. This indicates that MBX is financially healthy and has no problem in meeting its short term obligations.
MBX's Current ratio of 9.36 is amongst the best of the industry. MBX outperforms 87.50% of its industry peers.
MBX has a Quick Ratio of 6.37. This indicates that MBX is financially healthy and has no problem in meeting its short term obligations.
MBX has a better Quick ratio (6.37) than 87.50% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 9.36 | ||
| Quick Ratio | 6.37 |
3. Growth
3.1 Past
MBX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -44.66%.
MBX shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 8.58% yearly.
MBX shows a decrease in Revenue. In the last year, the revenue decreased by -4.65%.
Measured over the past years, MBX shows a quite strong growth in Revenue. The Revenue has been growing by 13.62% on average per year.
EPS 1Y (TTM)-44.66%
EPS 3Y8.58%
EPS 5YN/A
EPS Q2Q%-96.3%
Revenue 1Y (TTM)-4.65%
Revenue growth 3Y10.96%
Revenue growth 5Y13.62%
Sales Q2Q%-5.47%
3.2 Future
The Earnings Per Share is expected to grow by 51.83% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 21.86% on average over the next years. This is a very strong growth
EPS Next Y50%
EPS Next 2Y41.42%
EPS Next 3Y51.83%
EPS Next 5YN/A
Revenue Next Year7.14%
Revenue Next 2Y20.68%
Revenue Next 3Y21.86%
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 29.50, MBX can be considered very expensive at the moment.
91.67% of the companies in the same industry are more expensive than MBX, based on the Price/Earnings ratio.
When comparing the Price/Earnings ratio of MBX to the average of the S&P500 Index (27.15), we can say MBX is valued inline with the index average.
The Price/Forward Earnings ratio is 7.30, which indicates a rather cheap valuation of MBX.
100.00% of the companies in the same industry are more expensive than MBX, based on the Price/Forward Earnings ratio.
When comparing the Price/Forward Earnings ratio of MBX to the average of the S&P500 Index (21.60), we can say MBX is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 29.5 | ||
| Fwd PE | 7.3 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, MBX is valued cheaply inside the industry as 100.00% of the companies are valued more expensively.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of MBX indicates a rather cheap valuation: MBX is cheaper than 91.67% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 18.47 | ||
| EV/EBITDA | 8.54 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
MBX has an outstanding profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as MBX's earnings are expected to grow with 51.83% in the coming years.
PEG (NY)0.59
PEG (5Y)N/A
EPS Next 2Y41.42%
EPS Next 3Y51.83%
5. Dividend
5.1 Amount
MBX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX:MBX (6/30/2025, 7:00:00 PM)
0.295
-0.01 (-1.67%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners0.43%
Inst Owner ChangeN/A
Ins Owners14.97%
Ins Owner ChangeN/A
Market Cap41.54M
Analysts80
Price Target0.92 (211.86%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 29.5 | ||
| Fwd PE | 7.3 | ||
| P/S | 1.83 | ||
| P/FCF | 18.47 | ||
| P/OCF | 10.57 | ||
| P/B | 1.34 | ||
| P/tB | 1.53 | ||
| EV/EBITDA | 8.54 |
EPS(TTM)0.01
EY3.39%
EPS(NY)0.04
Fwd EY13.69%
FCF(TTM)0.02
FCFY5.41%
OCF(TTM)0.03
OCFY9.46%
SpS0.16
BVpS0.22
TBVpS0.19
PEG (NY)0.59
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.97% | ||
| ROE | 5.04% | ||
| ROCE | 5.96% | ||
| ROIC | 4.29% | ||
| ROICexc | 7.12% | ||
| ROICexgc | 8.69% | ||
| OM | 9.61% | ||
| PM (TTM) | 6.89% | ||
| GM | 57.74% | ||
| FCFM | 9.9% |
ROA(3y)4.84%
ROA(5y)-2.84%
ROE(3y)6.48%
ROE(5y)-11.45%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y-16.73%
ROICexcg growth 5Y20.32%
ROICexc growth 3Y-19.11%
ROICexc growth 5Y24.01%
OM growth 3Y-14.86%
OM growth 5Y15.81%
PM growth 3Y-7.25%
PM growth 5Y128.26%
GM growth 3Y0.68%
GM growth 5Y4.41%
F-Score6
Asset Turnover0.58
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.17 | ||
| Debt/FCF | 2.38 | ||
| Debt/EBITDA | 1.36 | ||
| Cap/Depr | 99.49% | ||
| Cap/Sales | 7.4% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 101.47% | ||
| Profit Quality | 143.69% | ||
| Current Ratio | 9.36 | ||
| Quick Ratio | 6.37 | ||
| Altman-Z | 3.36 |
F-Score6
WACC7.29%
ROIC/WACC0.59
Cap/Depr(3y)133.78%
Cap/Depr(5y)133.99%
Cap/Sales(3y)8.11%
Cap/Sales(5y)7.74%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-44.66%
EPS 3Y8.58%
EPS 5YN/A
EPS Q2Q%-96.3%
EPS Next Y50%
EPS Next 2Y41.42%
EPS Next 3Y51.83%
EPS Next 5YN/A
Revenue 1Y (TTM)-4.65%
Revenue growth 3Y10.96%
Revenue growth 5Y13.62%
Sales Q2Q%-5.47%
Revenue Next Year7.14%
Revenue Next 2Y20.68%
Revenue Next 3Y21.86%
Revenue Next 5YN/A
EBIT growth 1Y59.46%
EBIT growth 3Y-5.54%
EBIT growth 5Y31.58%
EBIT Next Year-29.47%
EBIT Next 3Y21.52%
EBIT Next 5YN/A
FCF growth 1Y310.13%
FCF growth 3Y41.04%
FCF growth 5YN/A
OCF growth 1Y260.45%
OCF growth 3Y27.25%
OCF growth 5Y155.41%